VBI Vaccines — SciVac Therapeutics — Investor Presentation (June 2016)
62 slides from VBI Vaccines's investor presentation, Jun 13, 2016
Slide 1: Key Opinion Leader Lunch: Advances in Vaccination Against Hepatitis B
C©LIFESCL ©) VBI VACCINES (© LIFESC! ra | \ Key Opinion Leader Lunch Advances in Vaccination Against Hepatitis B Hosted by VBI Vaccines (NASDAQ: VBIV | TSX: VBV) June 13 2016
Slide 2: Agenda
Agenda * Introduction ........ LifeSci Advisors * Significant Unmet Need for an Dr. Florian Schédel Enhanced Hepatitis B Vaccine * Sci-B-Vac™ : a 3" Generation ..................... Dr. Daniel Shouval Hepatitis B Vaccine with Enhanced Immunogenicity * Overview of VBI Vaccines Jeff Baxter VBI Vaccine
Slide 3: Significant Unmet Need for an Enhanced Hepatitis B Vaccine
Significant Unmet Need for an Enhanced Hepatitis B Vaccine Florian Schddel Independent Consultant Prev. VP of Vaccines Clinical Research, Merck
Slide 4: Hepatitis B Virus
Hepatitis B Virus LHBS (Pre-S1) SHBS (S) pe? Suesis)_ MBs (Pre-S2) 42nm. HBsAg — marker of infectivity Anti-HBs antibodies — marker of protection (induced by vaccination or following recovery from HBV
Slide 5: Hepatitis B Disease Progression
Hepatitis B Disease Progression 30% of chronically infected individualst® Acute Infection imal — = > 90% of infected infants progress to chronic diseasel!) Liver Cancer = < 5% of infected Liver Failure Chronic hepatitis B is the 6th immunocompetent adults (Decompensation} leading cause of liver prog
Slide 6: Worldwide HBV Infection
OEE Worldwide HBV Infection More than 2 billion people infected during lifetime Up to 2 million die each year from HBV infection Worldwide there are ~350-400 million HBsAg carriers Persistent HBV is considered a significant risk factor for development of primary liver cancer <50% liver cancer patien
Slide 7: Prevalence of Chronic Adult Hepatitis B Infection
Prevalence of Chronic Adult Hepatitis B Infection (2012) < ~ Prevalence of Hepatitis 8 Ii High: 2 3% Ill High intermediate: 5% -7% To Low Intermediate: 294 4% Low: <2% No Data Source: CDC 2016 Yellow Book Traveler's Health, Chapter 3; 7 Intp://wrwwne cde gov/travel/yellowbook/2016/infectious-disease
Slide 8: Immigration Trends to Europe and the US
Immigration Trends to Europe and the US Immigration by continent: 2000-2009 = 3.57 miljjon Asians > 8% (high) I 2% to 7% (intermediate! (< 2% (low)
Slide 9: EU Refugee Crisis Increasing Need for Superior HBV Vaccines
EU Refugee Crisis Increasing Need for Superior HBV Vaccines A STUDY PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2016 IN BARCELONA TESTED 793 REFUGEES FOR SEROLOGICAL MARKERS OF HBV INFECTION IN NORTHERN GERMANY: + The presence of Hepatitis B, was found in: * 2.3% of patients - measured by HBsAg *
Slide 10: Estimated HBV Prevalence Among Foreign-Born Americans
Estimated HBV Prevalence Among Foreign-Born Americans All regions 3.7 1,522,798 Asia TES 862,779 Central America 1.3 208,804 Caribbean 23 82,000 South America 16 46,614 Africa 11.8 196,338 Europe 2.2 114,174 Oceania 5.4 9,424 North America 0.3 2,665 Welch S, et al. AASLD 2008. Abstract 853 10
Slide 11: Chronic Hepatitis B in the US: Undiagnosed & Undertreated
Chronis Hepatitis B in the US: Undiagnosed & Undertreated Cohen C, etal. J Viral Hepat. 2011;18:377-383. u
Slide 12: Evolution of Strategies for Global Prevention of Hepatitis B Virus Infection
Evolution of Strategies for Global Prevention of Hepatitis B Virus Infection ° Immunization of risk groups HCW —Healthcare workers Spouses and contacts of HBsAg carriers Patients on haemodialysis People who inject drugs Institutionalized individuals MEM —men who have sex with men Babies born to HBV
Slide 13: WHO Position on Hepatitis B Vaccine
WHO Position on Hepatitis B Vaccine * NEWBORNS should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours * BIRTH DOSE should be followed by 2 or 3 doses to complete the primary series * CATCH-UP VACCINATION should be considered for cohorts of
Slide 14: Despite Significant Achievements, There Remains a High Unmet Need
___—_—————— ns] Despite Significant Achievements, There Remains a High Unmet Need + > one billion doses of HB vaccine have been administered worldwide with an excellent record of safety and efficacy * Seroprotection rates to anti-HBs are close to 100% in children and up to 95% in healthy young adult
Slide 15: Adult Hepatitis B Vaccination Coverage Remains Inadequate
SS Adult Hepatitis B Vaccination Coverage Remains Inadequate Reported US Hepatitis B Vaccination Coverage - 2014 Otherwise Healthy Adults aged 2 19 years 24.5% Adults aged 19-49 years 32.2% Adults age 2 50 years 15.7% High-Risk Chronic Liver Conditions 29.8% Diabetics — Age 19-59 years 23.5% Diabeti
Slide 16: Seroconversion Rates in Patient Subgroups
SL Seroconversation Rates in Patient Subgroups SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT Anti-HBs Seroconversion Rates After Hepatitis B Vaccination Neonates > 95% Age 2-19 ~99% Age 20-29 ~95% Age 30 - 39 ~90% Age 40-49 ~85% Age 50-59 ~70%
Slide 17: The Unmet Need: High-Risk Populations of Non-Responders & Low Responders
The Unmet Need: High-Risk Populations of Non- Responders & Low Responders to Conventional HBV Vaccination SEROCONVERSION RATES: * Cancer patients (children) ooo ee ccetees tenes “57% * Patients with chronic liver disease....................... . ~50% * Chronic renal failure & dialysis .........c:c0c
Slide 18: Current Approaches to Vaccination of Non- or Low Responders
Current Approaches to Vaccination of Non- or Low Responders to Conventional HBV Vaccination Means for improving immunogenicity of HBV vaccines * Increase dose and/or add more injections * Use PreS/S HBV vaccine expressed in mammalian cells ° Add amore immunogenic adjuvant than alum-hydroxide * Intra
Slide 19: Selected Monovalent HBV Vaccines
Selected Monovalent HBV Vaccines Source/ Brand Name —_ Expression in Envelope Manufacturer Countr Protein(s) Y Engerix B® Yeast Ss GSK Recombivax" Yeast 5 sD us Heberbiovac Yeast s vistecrolosia Cuba GenHevac B CHO S/Pre-S2* Pasteur-M. France Heplisav Yeast S Dynavax Pending Sci B Vac™ CHO $/PreS-1/
Slide 20: Sci B Vac: A Third Generation Hepatitis B Vaccine
Sci B Vac™ A Third Generation Hepatitis B Vaccine with Enhanced Immunogenicity Daniel Shouval Liver Unit Hadassah-Hebrew University Hospital Jerusalem, Israel
Slide 21: History of generations of HBV vaccines
History of 3 generations of HBV vaccines* I. 1981 - 1982: Plasma derived @s vaccines A Pres2 Third generation © Presi >) Mammalian Cell Il, 1986 : Recombinant HBV DNA afl Derived vaccine expressed in yeasts Il. 1990s : Recombinant pre-S/S vaccines expressed in mammalian cells Plasma Derived Vaccine
Slide 22: Generations of HBV Vaccines
3 Generations of HBV Vaccines PLASMA DERIVED rDNA YEAST rDNA MAMMALIAN CELL VACCINES DERIVED DERIVED VACCINES
Slide 23: Means for Improving the Immunogenicity of HBV Vaccines
___—_————— eens] Means for Improving the Immunogenicity of HBV Vaccines * Dual or triple antigen vaccines (Pre-S,/Pre-S,/S) ° New adjuvants: * Fendrix GSK™ (MPL /A&QS21) * Toll-like Receptors, e.g. Heplisav, Dynavax™ (TLR9, CoG ODNs) * ME59 (oil in water) * AgB/RC 529 (MPL, Corixa, Berna Biotech) *
Slide 24: Rationale for Developing HBV Vaccines with Enhanced Immunogenicity
__—_—_—_—————————————— ns] What is the Rationale for Developing HBV Vaccines with Enhanced Immunogenicity? * Non-response to conventional HBV vaccines in special populations ° Fast induction of immunity to HBV in defined populations * Low compliance with the 3-dose regimen of conventional HBV vaccin
Slide 25: Factors Related to Non-Response to Hepatitis B Vaccines
| Factors Related to Non-Response to Hepatitis B Vaccines ENHANCING * Genetically determined resistance ° Advanced age * Overweight * Age * Gender Pre-S * Smoking * Immune suppression * Chronic liver disease * Miscellaneous (RF, systemic disease) ‘raven DE, S31 Ann Int MedISEGIOEASE ATTENUATING ‘Alp
Slide 26: Sci-B-Vac: 3rd Generation HBV Vaccine
Sci-B-Vac™ : 3' Generation HBV Vaccine THE UNIQUE COMPOSITION OF HBV ENVELOPE PROTEINS IN SCI-B-VAC™ VS. YEAST-DERIVED PARTICLES Yeast derived particles formulated Mammalian cell derived particles With alum hydroxide in Engerix B® Formulated with alum hydroxide and Recombivax® in Sci B vac™ @ Santig
Slide 27: HBV Envelope Proteins
HBV Envelope Proteins v (128 amino acids) (55 amino acids) H+ + = “Large Protein” + = “Middle Protein” = “Major Protein” (226 amino acids)
Slide 28: The Unique Composition of HBV Envelope Proteins in Sci-B-Vac
___—_———————————————————— ns] The Unique Composition of HBV Envelope Proteins in Sci-B-Vac™ S Gene pre-S1___ pre-S2 Ss ATG ATG ATG TAA large protein(L) middie (M) small (2S + pres2+ protein (@) protein (S) preS1) (=S + preS2) Dane (HBV) particle preS1/S2/HBsAg preS2/HBsAg HBsAg # @6@ nucleo- capsid
Slide 29: Evidence of the Enhanced Immunogenicity of Sci-B-Vac
| Evidence of the Enhanced Immunogenicity of Sci-B-Vac™ To date, over 20 clinical studies have been completed in >3,000 patients immunized with Sci-B-Vac™ with an excellent safety record, including healthy adults, children and neonates Reference: Shouval D. et al. Enhanced immune response to hepatit
Slide 30: Anti-HBs Response in 18-29 Year Old Adults
SS Anti-HBs Response Following Immunization with Sci- B-Vac™ in 18-29 Year Old Adults (N=105) 1000004 VV Vv a = 10000 = g 1000 z = 100 5 = = 10 ° 1 o 1 2 6 ef 12 Months CO sto ME 10n9 Seroprotection Rates 2 mo: 79-83%, 6 mo: 97-98%, 12 mo: 100% Med Microbiol Immunol 2015;204:57-68
Slide 31: Comparative Immunogenicity of Sci-B-Vac vs Engerix-B After 3 Doses
Comparative Immunogenicity of Sci-B-Vac™ Vaccine to Engerix-B After 3 Doses Quantification of anti-HBs Hl topaim Biotep-B'ScrB-Vae e260 Wh SuaimiBitep-B'Sc-VKe e253 BE 20p0%m Engin-B ne2t Impact of body weight on anti-HBs levels % of subjects <10 11-100 101-1000 1001-10000 >10000 AnticHBs Titers (mi
Slide 32: Comparative Immunogenicity of Hepatitis B Vaccines
eee Comparative Immunogenicity of Hepatitis B Vaccines N = 36 (20M/16F) Mean Age — 23 years (19-28) Protocol: — 2 doses of Sci-B-Vac™ 10ug/dose — 2 doses of Engerix B 20ug/dose Time of intra-muscular injections: Day 0 & 6 months ‘Shapira MY, ZeraE, Adler R, ShouvalD. Rapid seroprotection against hep
Slide 33: Comparative Seroprotection of Two HBV Vaccines
Comparative Seroprotection of Two HBV Vaccines Response After 1 and 2 Doses x fe & Gb oO 2 2 a 2 oO ti) time after priming (months) @ Sci-B-Vac™ rR a Hl Engerix B Shapira M &Shouval D et al. J Hepatology 2000 $
Slide 34: Immunogenicity of Sci-B-Vac in Neonates
Immunogenicity of Sci-B-Vac™ in Neonates Immunogenicity of Sci-B-Vac in Neonates by anti-HBs levels (n=205, Comparative study) 14000 12000 40100___ 100100 jw/niwsay saH-nuy Pe eeee o_o) DSc.BVeczsug DEE 10u9 A B 34
Slide 35: Immunogenicity in Neonates Born to HBsAg+ Mothers (Dose Response)
a Immunogenicity of Sci-B-Vac™ in Neonates Born to HBsAg+ Mothers (Dose Response) sy i
Slide 36: Immunogenicity in Neonates Born to HBsAg+ Mothers (by HBeAg Status)
a Immunogenicity of Sci-B-Vac™ in Neonates Born to HBsAg+ Mothers (by HBeAg Status)
Slide 37: Robust T- and B-cell Response in Non- and Low-Responders
Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Krawczyk A, Ludwig C, Jochum C, Fiedler M, Heinemann FM, Shouval D, Roggendorf M, Roggendorf H, Lindemann M Vaccine 2014,32 5077-
Slide 38: Pre S/S Vaccine in Non-Responders
eee Pre S/S Vaccine in Non-Responders SUMMARY: * Significantly higher immunogenicity after 2 additional injections of 3' generation PreS/S vaccine compared to conventional S vaccine at anti-HBs 10 and 100 |U/I level * Influence of age, BMI and gender less pronounced in 34 generation PreS/S vaccinees
Slide 39: Sci-B-Vac Dose Ranging Study: Neonates Vietnam
a Sci-B-Vac™ Dose Ranging Study : Neonates Vietnam 2 i=} % of subjects N is} f=} <10 11-100 101-1000 1001-10000 >10000 Anti-HBs Titers (mlU/ml) 11-4b 39
Slide 40: Efficacy in Patients Receiving Lamivudine After Liver Transplantation
Efficacy of a Pre-S/S Sci-B-Vac™ Vaccine in Patients Receiving Lamivudine Prophylaxis After Liver Transplantation for Chronic Hepatitis B mt-HBstita mll/mL) 1 o 123 4 5 6 7 8 9 WO IL 12:13 146 IS 16 17 18 = = ‘time (roonths) Lo et al. Am J Transplantation 2007;7:434
Slide 41: Enhanced Immunogenicity in Dialysis Patients with Kidney Failure
Enhanced Immunogenicity of Sci-B-Vac™ in Dialysis Patients with Kidney Failure iit @ HB-Vax- II 10 pig (n=12) Anti-HBs, mlU/ml 60 90 180 210 days
Slide 42: Special Subpopulations which may Benefit from Sci-B-Vac
_—_————————————————— ns] Special Subpopulations which may Benefit from Immunization with Sci-B-Vac™ * Non-responders to conventional HBV vaccines * Healthcare workers involved in exposure prone procedures * Immune suppressed patients at risk (i.e. transplant patients, candidates for chemotherapy, pa
Slide 43: Summary: Sci-B-Vac
Summary : Sci-B-Vac™ ¥ Mimics all three HBV surface antigens of the hepatitis B virus v Offers rapid onset of protection v Induces high levels of anti-HBs antibodies v Can be administered at lower doses than other currently available HBV vaccines v Free of next-generation adjuvants ¥ Produced in mam
Slide 44: Thank You
The Hadassah Medical Center in Jerusalem Thank You
Slide 45: Executive Summary
©) VBI VACCINES EXECUTIVE SUMMARY KEY ORINION LEADER ‘a asics IN VA ws : NASDAQ: VBIV TSX: VBV a JUNE 13 2016
Slide 46: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collective
Slide 47: Agenda
| Agenda 1. INTRODUCTION TO VBI VACCINES 2. SCI-B-VAC™ OPPORTUNITY 3. SUMMARY NasDaa: VBI | TSX: vev a
Slide 48: 1. Introduction to VBI Vaccines
w\Om, We) 1. Introduction to VBI Vaccines y S Zs
Slide 49: About VBI Vaccines
fv About VBI Vaccines VBI Vaccines Inc. (NASDAQ: VBIV) is developing novel technologies that seek to expand vaccine protection in significant markets of unmet medical need. VBI OVERVIEW * NASDAQ: VBIV {as at close on 6/10/2016) © Common Stock Currently Outstanding: 33MM Shares © Share Price: $4.36 M
Slide 50: Leading Immunology Innovation in Significant Markets with High Unmet Need
Leading Immunology Innovation in Significant Markets with High Unmet Need PIPELINE + Hepatitis 8 Vaccine: 3 generation vaccine targeting non-responders to standard of care TECHNOLOGY PLATFORMS + Enveloped Virus-Like Particle (“eVLP") platform closely mimics viruses and induces potent and durable imm
Slide 51: VBI Vaccines Board of Directors
VBI Vaccines Board of Directors DR. STEVEN GILLIS CHAIRMAN OF THE BOARD KX immunex ARCH Venture Partners lie ¥ 1 DR. MICHEL DE WILDE, PH.D. A GlaxoSmithktine e- ‘J SANOFI SCOTT REQUADT, JD ~~ clarus e Teaxsrorm SAM CHAWLA )\\ PERCEPTIVE ADVISORS & ¥ UBS JEFF BAXTER PRESIDENT & CEO
Slide 52: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint HEADQUARTERS — CAMBRIDGE, MA = CEO, CSO, CTO, CFO+ 4 FTEs = Central location in biotechnology hub RESEARCH OPERATIONS - OTTAWA, CANADA = CMO+~25 FTEs = World-class R&D team and facility MANUFACTURING FACILITY - REHOVOT, ISRAEL = ~50 FTES = GMP manufacturing facility for
Slide 53: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple nt eae in Infectious Disease and Oncology Preclinical Phase! © Phasell Phase Ill Infectious Disease eee) Drews (Licensed in 15 countries) Bae Expected Ph CMV (vei-15014) Stare HI 2016 RSV [an Immuno-Oncology GBM Undisclosed Undisclosed Undisclosed [ae [est] NasDaa: VBI
Slide 54: 2. Sci-B-Vac Opportunity
w\Om, We) 2. Sci-B-Vac™ Opportunity y S Zs
Slide 55: Sci-B-Vac Approved Markets
Sci-B-Vac™ (15) Approved Markets ONLY COMMERCIAL HBV VACCINE TO MIMIC ALL 3 VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 300,000+ PATIENTS
Slide 56: Excerpt of Publicly Available Sci-B-Vac Data
| Excerpt of Publicly Available Sci-B-Vac™ Data SEVERAL PHASE II & Ill STUDIES HAVE BEEN CONDUCTED IN > 4,500 PATIENTS- RESULTS OF WHICH INCLUDE: Size Population Sci-B-Vac™ 1° Generation HBV Vaccine 98% SPR - month 6, post 2 injection; N=105 dul: foung adults 100% SPR - post 3 injection NA 56% SPR -
Slide 57: Overview of Commercial Opportunity
Overview of Commercial Opportunity IMPLICATIONS FOR KEY PATIENT SEGMENTS INCLUDE: + High unmet need Diabetics + Easy patient identification + Superiority vs. current SoC may warrant small price premium Large population — small market penetration will still produce large commercial opportunity + Unme
Slide 58: Existing Requests for Named Patient Sales
| Existing Requests for Named Patient Sales STRONG DEMAND FOR SCI-B-VAC™ OUTSIDE OF ISRAEL — SCIVAC HAS RECEIVED THE FOLLOWING REQUESTS FOR ACCESS TO SCI-B-VAC™ IN THE BELOW MARKETS: Named Patient Use: + April 10, 2016 — India (patient) + March 31,2016 Germany (patient) + March 1, 2016 — Germany (ho
Slide 59: 3. Summary
\) 3. Summary Y Sy
Slide 60: VBI Vaccines Strategic Vision
————————————— ee Cea VBI Vaccines Strategic Vision BECOME A LEADER IN IMMUNOLOGY INNOVATION BY LEVERAGING VBI ASSETS & CAPABILITIES IN SIGNIFICANT MARKETS WITH HIGH UNMET MEDICAL NEEDS Infectious Disease Immuno-Oncology Partnership Programs Target public health Explore combinations with Leverage ass
Slide 61: Value Proposition for VBI Vaccines
—————————————— en ee) Value Proposition for VBI Vaccines FOUR KEY VALUE DRIVERS IN NEXT 18 MONTHS: Sci-B-Vac™: Meeting with EMA/FDA H2 2016 to determine clinical development path ® CMV: CTA approval and Ph | trial start H1 2016 GBM: Pre-IND meeting with FDA H1 2016 to determine clinical development
Slide 62: VBI Vaccines Inc. contact details
wy Y S 7M Mpyi\\ VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com
SciVac Therapeutics — Investor Presentation (June 2016) on 6ix